Oddo BHF confirms its "neutral" recommendation on Virbac shares, with an unchanged target price of 320 euros after the laboratory confirmed its roadmap.

The analyst reports that the strategic development zones remain the USA and China, and that Virbac intends to pursue its competitiveness (investments) and R&D efforts, with a focus on ruminants and companion animals (+pigs and aquaculture).

Oddo BHF also points out that the company has confirmed its interest in external growth as part of its acquisition strategy. It also deplores the lack of timing in the appointment of a new CEO, even though the departure of the previous CEO was announced 9 months ago.

Thus, "the more marked growth profile in H2 and the acquisition and appointment of a CEO appear to be potential catalysts for regaining confidence", stresses Oddo BHF.

Against this background, the analyst leaves his estimates unchanged. We believe that the downside is limited, but the half-year sequencing of growth and results will be more favorable in H2 2025 (due to base effects / H1 2024: sales: +15% and ROC: +37%)', it concludes


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.